Sermorelin: Dosing Protocols

Dosing Overview#

Sermorelin dosing has been established through its former FDA-approved indications and subsequent clinical research. The dosing approach differs significantly from exogenous GH replacement because sermorelin works by stimulating endogenous GH production, which is inherently self-regulating through somatostatin feedback. This section presents dosing information from published clinical studies and former prescribing information for educational purposes.

FDA-Approved Dosing (Historical)#

Pediatric GH Deficiency#

The formerly approved dose for children with idiopathic growth hormone deficiency was 30 mcg/kg body weight administered as a single subcutaneous injection at bedtime. This protocol was based on clinical trials demonstrating sustained increases in height velocity over 12 months of treatment.

Key aspects of the pediatric protocol:

• Weight-based dosing: 30 mcg/kg ensures appropriate dose scaling across different body sizes
• Bedtime administration: Aligns with the natural nocturnal GH pulse, maximizing physiological response
• Treatment duration: Studies showed continued growth benefits over at least 12 months with no evidence of tachyphylaxis
• Monitoring: Height velocity, IGF-1 levels, and bone age assessed at regular intervals

Diagnostic Testing#

For GH deficiency diagnosis, sermorelin was administered as an intravenous bolus of 1 mcg/kg body weight. Blood samples for GH measurement were drawn at baseline and at 15, 30, 45, and 60 minutes post-injection. A peak GH response above 7-10 ng/mL was considered evidence of intact pituitary somatotroph function.

Adult Research Protocols#

Clinical research in adults has utilized various dosing regimens, though no standardized adult protocol exists from controlled trials:

Standard Adult Protocol#

Based on published research and clinical practice reports, a common adult protocol involves:

• Dose: 100-300 mcg per injection
• Frequency: Once daily, administered 30 minutes before bedtime on an empty stomach
• Duration: 3-6 month cycles with periodic reassessment
• Fasting: Food intake, particularly carbohydrates and fats, within 90 minutes before injection may blunt the GH response

Combination Protocols#

When combined with a GHRP such as ipamorelin, lower doses of each agent may be used due to synergistic effects:

• Sermorelin: 100 mcg
• GHRP (e.g., ipamorelin): 100-300 mcg
• Timing: Both injected simultaneously or sequentially, once or twice daily
• Rationale: Synergistic amplification of GH release through dual pathway activation

Administration Guidelines#

Reconstitution#

1. Remove the flip-off cap from the sermorelin vial and wipe the rubber stopper with an alcohol swab
2. Using a sterile syringe, draw up the appropriate volume of bacteriostatic water (typically 2-3 mL per 5 mg vial)
3. Inject the diluent slowly along the side of the vial to minimize foaming
4. Gently swirl the vial until the powder is completely dissolved; do not shake vigorously
5. Inspect the solution for clarity and absence of particulate matter

Concentration After Reconstitution#

Injection Technique#

Sermorelin is administered via subcutaneous injection:

1. Prepare the injection site: Clean with alcohol swab and allow to air dry
2. Draw the dose: Using an insulin syringe (29-31 gauge, 0.5-1 mL), draw the calculated volume
3. Inject: Pinch a fold of skin at the chosen site, insert the needle at a 45-90 degree angle, and inject slowly
4. Post-injection: Hold gauze over the site briefly; do not massage the injection area

Injection Site Rotation#

Rotate injection sites systematically to prevent lipodystrophy and ensure consistent absorption:

• Abdomen: The preferred site for most patients; inject at least 2 inches from the navel, rotating among quadrants
• Thigh: The outer quadricep provides ample subcutaneous tissue
• Upper arm: The deltoid area offers an alternative site

Timing Optimization#

The timing of sermorelin administration significantly affects its efficacy:

• Bedtime administration: Injecting 30 minutes before sleep aligns with the natural nocturnal surge in GH secretion, potentiating the response
• Fasting state: GH release is inhibited by hyperglycemia and elevated free fatty acids. A minimum 90-minute fast before injection is recommended
• Exercise timing: Exercise itself stimulates GH release; administering sermorelin post-exercise may provide an additive effect
• Consistency: Regular daily administration at the same time is important for maintaining the stimulated GH secretory pattern

Dose Adjustment Considerations#

Factors that may require dose modification include:

• Age: Older adults may require higher doses due to reduced pituitary responsiveness
• BMI: Obesity is associated with reduced GH response to GHRH; dose adjustment may be needed
• IGF-1 response: Monitoring IGF-1 levels allows individualized dose titration
• Concomitant medications: Glucocorticoids, thyroid hormone status, and other medications affect GH response
• Adverse effects: Dose reduction should be considered if side effects emerge

Storage and Handling#

Proper storage is essential for maintaining sermorelin's potency:

• Lyophilized (unreconstituted): Store at controlled room temperature (20-25 degrees Celsius) or refrigerated (2-8 degrees Celsius). Stable for the manufacturer-indicated shelf life
• Reconstituted solution: Must be refrigerated at 2-8 degrees Celsius. Use within 14 days of reconstitution
• Avoid freezing: Do not freeze reconstituted solution, as this may cause protein aggregation and loss of activity
• Light protection: Store in original packaging or wrap in foil to protect from light degradation
• Travel: Transport in insulated cooler bags with ice packs; avoid exposure to extreme temperatures

Related Reading#

• Sermorelin overview and research guide
• Sermorelin side effects profile
• Sermorelin research evidence